The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin

Journal of Clinical Pharmacology

Volumn 39, Issue 1, 1999, Pages 86-90

  Lin, Jennifer C ^b   Ito, Matthew K ^a   Stolley, Stephen N ^b   Morreale, Anthony P ^b   Marcus, David B ^b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMIODARONE; CIMETIDINE; COLESTYRAMINE; GEMFIBROZIL; GRISEOFULVIN; LEVOTHYROXINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PHENYTOIN; PRAVACOHOL; PRAVASTATIN; QUINIDINE; SIMVASTATIN; SULFONYLUREA; UNCLASSIFIED DRUG; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; FEMALE; HUMAN; HYPERLIPIDEMIA; MALE; PHARMACODYNAMICS; RETROSPECTIVE STUDY;

AGED; ANTICHOLESTEREMIC AGENTS; ANTICOAGULANTS; CLINICAL TRIALS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PRAVASTATIN; RETROSPECTIVE STUDIES; SIMVASTATIN; TIME FACTORS; WARFARIN;

EID: 0032895810     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922007598     Document Type: Article

References (28)

1. Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: the West of Scotland Coronary Prevention Study. N Engl J Med 1995;333:1301-1307.
3. Harder S, Thurmann P: Clinically important drug interactions with anticoagulants: an update. Clin Pharmacokinet 1996;30(6):416-444.
4. Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H: Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995;108(4):231S-246S.
5. Ahmad S: Lovastatin warfarin interaction. Arch Intern Med 1990;150:2407.
6. Hoffman HS: The interaction of lovastatin and warfarin. Conn Med 1992;56:107.
7. Trenque T, Choisy H, Germain M-L: Pravastatin: interaction with oral anticoagulant? Br Med J 1996;312:886.
8. Trilli LE, Kelley CL, Aspinall SL, Kroner BA: Potential interaction between warfarin and fluvastatin. Ann Pharmacother 1996;30:1399-1402.
9. Kline SS, Harrell CC: Potential warfarin-fluvastatin interaction. Ann Pharmacother 1997;31(6):790.
10. Stern R, Abel R, Gibson GL, Besserer J: Atorvastatin does not alter the anticoagulant activity of warfarin. /J Clin Pharmacol 1997;37:1062-1064.
11. Walker JF: Simvastatin: the clinical profile. Am J Med 1989;87(4A):44S-46S.
12. Gaw A, Wosornu D: Simvastatin during warfarin therapy in hyperlipoproteinaemia. Lancet 1992;340:979-980.
13. Keech A, Collins R, MacMahon S, Armitage J, Lawson A, Wallendszus K, et al: Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J 1994;15:255-269.
14. Grau E, Perella M, Pastor E: Simvastatin-oral anticoagulant interaction. Lancet 1996;347:405-406.
15. ® Protime Reagent Cartridge package insert. Boehringer Mannheim Corporation, 1994.
16. Rolan PE: Plasma protein binding displacement interactions: why are they still regarded as clinically important? Br J Clin Pharmacol 1994;37:125-128.
17. Tse FLS, Nickerson DF, Yardley WS: Binding of fluvastatin to blood cells and plasma proteins. J Pharm Sci 1993;82(9):942-947.
18. Feely J, O'Connor P: Effects of HMG-CoA reductase inhibitors on warfarin binding. Drug Invest 1991;5:315-316.
19. Lennernas H, Fager G: Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Clin Pharmacokinet 1997;32(5):403-425.
20. Atorvastatin (Lipitor) prescribing information. Morris Plains, NJ: Warner-Lamber Company, December 1996.
21. Transon C, Leemann T, Dayer P: In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1996;50:209-215.
22. Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, Ploschke J, et al: Metabolism of cerivastatin by human liver microsomes in vitro. Drug Metab Dispos 1997;25(3):321-331.
23. Ito MK: Effects of extensive and poor gastrointestinal metabolism on the pharmacodynamics of pravastatin. J Clin Pharmacol 1998;38:331-336.
24. Neuvonen PJ, Kantola T, Kivisto KT: Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998;63:332-341.
25. Bertz RJ, Granneman GR: Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32(3):210-258.
26. Godbillon J, Richard J, Gerardin A, Meinertz T, Kasper W, Jahnchen E: Pharmacokinetics of the enantiomers of acenocoumarol in man. Br J Clin Pharmacol 1981;12:621-629.
27. Hermans JJR, Thijssen HHW: Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. Br J Pharmacol 1993;110:482-490.
28. Mentre F, Pousset F, Comets E, Plaud B, Diquet B, Montalescot G, et al: Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients. Clin Pharmacol Ther 1998;63:64-78.